Surgery for a post-chemotherapy residual mass in seminoma.

Purpose: We attempted to select patients for surgery of post-chemotherapy residual mass in advanced seminoma.

Materials And Methods: A total of 55 patients with advanced seminoma underwent surgical exploration of a mass seen on computerized tomography (CT) after chemotherapy. Residual masses were defined radiographically as smaller or larger than 3 cm.

Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center.

Purpose: Guidelines for management of postchemotherapy residual mass in patients with advanced seminoma remain controversial. We sought to characterize independent prognostic factor(s) for persistence of tumor to identify patients with a high risk of residual carcinoma.

Patients And Methods: One hundred four patients with advanced seminoma were assessed.

Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors.

Fifteen patients with advanced, cisplatin-refractory germ cell tumors (GCT) were treated on a phase II trial with topotecan. None of the 14 evaluable patients achieved a complete or partial response. Myelosuppression was the major toxicity.